BeOne Medicines (ONC) Finished Goods (2017 - 2026)

BeOne Medicines (ONC) has 5 years of Finished Goods data on file, last reported at $298.2 million in Q1 2026.

• On a quarterly basis, Finished Goods changed N/A year-over-year to $298.2 million in Q1 2026; TTM through Mar 2026 was $298.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $249.4 million, down 5.65% from the prior year.
• Finished Goods for Q1 2026 stood at $298.2 million, up from $249.4 million in the prior quarter.
• Over the last five years, Finished Goods for ONC reached as high as $298.2 million in Q1 2026 and fell as low as $249.4 million in Q4 2025.
• Historically, Finished Goods has averaged $270.6 million across 3 years, with a median of $264.3 million in 2024.
• On a YoY basis, Finished Goods climbed as much as 5.65% in 2025 and fell as far as 5.65% in 2025.
• Year by year, Finished Goods stood at $264.3 million in 2024, then fell by 5.65% to $249.4 million in 2025, then increased by 19.57% to $298.2 million in 2026.
• Per Business Quant data, the three most recent Finished Goods figures were $298.2 million in Q1 2026, $249.4 million in Q4 2025, and $264.3 million in Q4 2024.